Publication
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (13)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 13
- cancerMalignant Neoplasmcivic_curation1.00
- drugSelumetinibcivic_curation1.00
- geneBRAFcivic_curation1.00
- geneHRAScivic_curation1.00
- geneKRAScivic_curation1.00
- geneNF1civic_curation1.00
- geneNRAScivic_curation1.00
- variantBRAF V600Ecivic_curation1.00
- variantHRAS Mutationcivic_curation1.00
- variantKRAS Mutationcivic_curation1.00
- variantNF1 Inactivating Mutationcivic_curation1.00
- variantNF1 Mutationcivic_curation1.00
- variantNRAS Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 35363510
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF V600E + HRAS Mutation + KRAS Mutation + NF1 Inactivating Mutation + NRAS MutationHRASNF1BRAFKRASNRAS1 | ||||||||
| Selumetinib | Malignant NeoplasmALIAS | Predictive | B | Does Not Support Sensitivity Response | 3 | accepted | EID11696In this Phase II study, 20 patients harboring activating RAS gene mutations (KRAS = 8, NRAS = 3. HRAS = 1), BRAF V600E mutations, and NF1 inactivating mutations (n=7) were treated with Selumetinib. No… (full text at CIViC) PMID 35363510 · Eckstein et al., 2022 · Open in CIViC | civic |
| BRAF V600E + HRAS Mutation + KRAS Mutation + NF1 Mutation + NRAS MutationHRASBRAFNF1KRASNRAS1 | ||||||||
| Selumetinib | Malignant NeoplasmALIAS | Predictive | B | Does Not Support Sensitivity Response | 3 | accepted | EID11681In this phase II study of the arm E of the NCI-COG pediatric MATCH trial, 20 patients (median age: 14) were treated with Selumetinib. High-grade glioma (n=7) and rhabdomyosarcoma (n=7) were the most c… (full text at CIViC) PMID 35363510 · Eckstein et al., 2022 · Open in CIViC | civic |